Pluripotente Stammzellen zur Zellersatztherapie des Diabetes mellitus

Zusammenfassung

Der Einsatz von pluripotenten Stammzellen (PSCs) in der Zellersatztherapie des Diabetes mellitus stellt eine vielversprechende Alternative zur Insulinsubstitution dar. Die in vitro Differenzierung von humanen oder murinen embryonalen Stammzellen erzeugt reproduzierbar pankreatische Vorläuferzellen, aber bislang noch keine authentischen insulinproduzierenden Betazellen. Induzierte pluripotente Stammzellen könnten sich möglicherweise als weitere Ausgangsquelle für die Zellersatztherapie eignen. Diese patientenspezifischen Stammzellen werden durch Reprogrammierung erzeugt, akkumulieren allerdings während der Reprogrammierung genetische und epigenetische Fehler, was bisher eine humantherapeutische Anwendung ausschließt.

Abstract

The use of pluripotent stem cells (PSCs) harbours great potential for a future use in the cell replacement therapy of diabetes mellitus. The in vitro differentiation of human or mouse embryonic stem cells has yielded pancreatic progenitor cells, but not authentic insulin-producing beta cells. Induced pluripotent cells are a class of a pluripotent stem cells potentially suited as a cell source for cell replacement therapy. These patient specific pluripotent cells are generated by reprogramming but unfortunately accumulate genetic and epigenetic errors during reprogramming, precluding their use for therapeutic purposes in humans.

Schlüsselwörter

Diabetes mellitus - Transplantation - Zellersatztherapie - pluripotente Stammzellen

Keywords

diabetes mellitus - transplantation - cell replacement therapy - pluripotent stem cells

• Literatur

• 1 Borowiak M, Maehr R, Chen S et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 2009; 4: 348-358
• 2 Cnop M, Welsh N, Jonas JC et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54 (Suppl 2): 97-107
• 3 D'Amour KA, Bang AG, Eliazer S et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006; 24: 1392-1401
• 4 Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-226
• 5 Jörns A, Günther A, Hedrich HJ et al. Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 2005; 54: 2041-2052
• 6 Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009; 27: 1050-1056
• 7 Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26: 443-452
• 8 Lenzen S. Die Rolle der Betazelle im Diabetes mellitus. Dtsch Med Wochenschr 2011; 136: 1123-1127
• 9 Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008; 36: 343-347
• 10 Limbert C, Path G, Jakob F et al. Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus. Diabetes Res Clin Pract 2008; 79: 389-399
• 11 Matveyenko AV, Georgia S, Bhushan A et al. Inconsistent formation and nonfunction of insulin-positive cells from pancreatic endoderm derived from human embryonic stem cells in athymic nude rats. Am J Physiol Endocrinol Metab 2010; 299: E713-720
• 12 Naujok O, Burns C, Jones PM et al. Insulin-producing surrogate beta-cells from embryonic stem cells: are we there yet?. Mol Ther 2011; 19: 1759-1768
• 13 Naujok O, Francini F, Picton S et al. A new experimental protocol for preferential differentiation of mouse embryonic stem cells into insulin-producing cells. Cell Transplant 2008; 17: 1231-1242
• 14 Rahier J, Guiot Y, Goebbels RM et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10 Suppl 4: 32-42
• 15 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14
• 16 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676
• 17 Waldhäusl W, Lenzen S. Kohlenhydrat-Stoffwechsel. In: Pathophysiologie – Molekulare, zelluläre, systemische Grundlagen von Krankheiten. Wien: Wilhelm Maudrich Verlag; 2007
• 18 Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-215